Thyroid papillary carcinomas are characterized by RET/ PTC rearrangements that cause the tyrosine kinase domain of the RET receptor to fuse with N-terminal sequences encoded by heterologous genes. This results in the aberrant expression of a ligand-independent and constitutively active RET kinase. We analysed actin reorganization induced by the RET/PTC1 oncogene in PC Cl 3 rat thyroid epithelial cells. Dierently from oncogenes Src, Ras and Raf, RET/PTC1 caused actin ®laments to form prominent stress ®bers. Moreover, stress ®bers were identi®ed in human thyroid papillary carcinoma cell lines harboring RET/PTC1 rearrangements but not in thyroid carcinoma cells negative for RET/PTC rearrangements. RET/MEN 2A, a constitutively active but unrearranged membrane-bound RET oncoprotein, did not induce stress ®bers in PC Cl 3 cells. Induction of stress ®bers by RET/PTC1 was restricted to thyroid cells; it did not occur in NIH3T3 ®broblasts or MCF7 mammary cells. RET/PTC1-mediated stress ®ber formation depended on Rho but not Rac small GTPase activity. In addition, inhibition of Rho, but not of Rac, caused apoptosis of RET/PTC1-expressing thyroid cells. We conclude that Rho is implicated in the actin reorganization and cell survival mediated by the chimeric RET/PTC1 oncogene in thyroid epithelial cells, both phenotypes being cell type-and oncogene typespeci®c. Oncogene (2001) 20, 6973 ± 6982.
Introduction
Papillary thyroid carcinoma (PTC), the most common thyroid malignancy in humans, is characterized by recombination events between the RET-tyrosine-kinase-encoding domain and heterologous genes that lead to the generation of chimeric RET/PTC oncogenes. RET/PTC variants dier in the RET fusion partner (Jhiang, 2000) . RET/PTC1 (the H4-RET fusion) is one of the most prevalent variants (Grieco et al., 1990) . RET/PTC oncogenes are consistently found in radiation-associated thyroid carcinomas (Jhiang, 2000) . They are very frequent in clinically silent small thyroid tumors, and are probably early tumorigenic events (Viglietto et al., 1995) . RET/PTC transgenic mice develop papillary thyroid carcinomas, suggesting that these oncogenes play a causative role in thyroid tumorigenesis (Jhiang, 2000) .
RET, a transmembrane tyrosine kinase, is the receptor for growth factors of the glial cell-derived neurotrophic factor (GDNF) family. The GDNF family consists of four GDNF ligands (GFL): GDNF, neurturin (NTN), persephin (PSP) and artemin (ART). GFL proteins signal through multi-component receptor complexes constituted by RET and a ligand-binding GDNF family receptor, designated the a subunit (GFRa1, 2, 3 and 4). The GFRa subunits are attached to the cell membrane by glycosyl-phosphatidylinositol (GPI)-anchors (Airaksinen et al., 1999) . Mice de®cient in GDNF, RET or GFRa1 failed to undergo metanephric and enteric neuron development, which demonstrates that this ligand/receptor complex plays an essential role in development (Airaksinen et al., 1999) . Loss-of-function mutations in RET cause defective intestinal innervation and congenital megacolon in humans (Jhiang, 2000) . Gain-of-function germ line point mutations in RET result in inherited multiple endocrine neoplasia types 2A and 2B (MEN 2A, MEN 2B) and familial medullary thyroid carcinoma (FMTC) (Ponder, 1999) .
Little is known about the signaling pathways of RET/PTC oncogenes in thyroid tumors; it is also unknown whether the RET/PTC rearrangements modify the signaling pathways of the RET kinase rather than simply up-regulate them. RET/PTC proteins are cytosolic and contain coiled-coil domains donated by the fusion partner; the coiled-coil domains mediate dimerization and ligand-independent activation of the RET/PTC kinase. Constitutive dimerization and tyr-osine phosphorylation of RET/PTC proteins result in constant up-regulation of RET signaling. The cytoplasmic domain of RET contains autophosphorylated tyrosines that recruit such signaling molecules as adaptor proteins (Grb2, Grb7, and Grb10) (Pandey et al., 1996; Alberti et al., 1998) , phospholipase C g (Borrello et al., 1996) , Shc (Asai et al., 1996; Arighi et al., 1997; Lorenzo et al., 1997) , the PDZ-and LIMdomain-containing protein Enigma (Durick et al., 1998) , Gab (Besset et al., 2000; Hayashi et al., 2000) , IRS-1 (Melillo et al., 2001a) and Frs2 (Melillo et al., 2001b) . RET stimulation results in activation of the Ras/Raf/MAPK, PI3K/Akt (De Vita et al., 2000; Segoun-Cariou and Billaud, 2000) , JNK (Chiariello et al., 1998; Hayashi et al., 2000) and Src signaling pathways (Melillo et al., 1999) .
The Rho family of Ras GTPases is constituted by Cdc42, RhoA and Rac1 (the latter two are henceforth referred to as Rho and Rac, respectively) (Bar-Sagi and Hall, 2000; Van Aelst and D'Souza-Schorey, 1997; Zohn et al., 1998) . As reviewed by Scita et al. (2000) , Rho GTPases are controlled by GTP exchange factors (GEF), mainly oncogenes (Cerione and Zheng, 1996) , Rho GDP-dissociation inhibitory factors (RhoGDI) and GTPases activating proteins (GAP). Several of these regulators have tissue-speci®c expression (Zohn et al., 1998) . Rho proteins function as molecular switches and so control multiple cellular processes ( Bar-Sagi and Hall, 2000; Zohn et al., 1998) . Most prominent are their eects on the actin cytoskeleton. Cdc42 induces ®lopodia (thin, ®nger-like cytoplasmic extensions containing actin bundles), Rac1 induces membrane rues and lamellipodia (curtainlike extensions consisting of thin protrusive actin sheets) and Rho causes the formation of stress ®bers (actin bundles that traverse the cell and promote cell attachment to the extracellular matrix via focal adhesions) Kjoller and Hall, 1999) . Finally, Rho GTPases exert oncogenic eects and regulate neoplastic transformation mediated by Ras, Dbl, v-abl, G proteincoupled receptors and G proteins (Scita et al., 2000) . Recently, RhoC was found to play an important role in the progression of melanoma cells to a metastatic phenotype (Clark et al., 2000) .
The rat thyroid epithelial cell line PC Cl 3 expresses thyroid dierentiation markers (thyroglobulin, thyroperoxidase and iodide transporter) and depends on thyrotropin (TSH) for growth (Fusco et al., 1987) . Therefore, PC Cl 3 cells are a valuable model with which to study the phenotypic eects of oncogenes in dierentiated epithelial cells. We have reported previously that PC Cl 3 cells transfected with RET/PTC1 (PC-PTC) lose the dierentiated phenotype and TSHdependency for proliferation (Santoro et al., 1993) . In the present study we have investigated the role of Rho family GTPases in PC-PTC cells and in neoplastic cells derived from human thyroid carcinomas harboring RET/PTC1 rearrangements. Here we show that Rho plays a speci®c role in cytoskeleton reorganization and cell survival mediated by RET/PTC in thyroid cells.
Results

RET/PTC1 promotes the organization of actin into stress fibers in PC Cl 3 cells
We analysed actin rearrangement in PC-PTC cells with respect to parental PC Cl 3 cells by staining cells with rhodamine-conjugated phalloidin. PC-PTC cells had many thick actin bundles that were arranged in long stress ®bers, whereas parental cells had very few, thin and short actin ®laments (Figure 1a) . Stress ®bers appeared in PC-PTC cells as early as 4 h after plating, whereas stress ®bers did not appear in parental cells even several days after plating (not shown). PC-PTC cells were on average much larger than parental cells (Figure 1a) .
To ascertain whether this phenotype was speci®c of RET/PTC1-oncogene-expressing cells or whether it was typical of PC Cl 3 cell transformation, we analysed actin organization in PC Cl 3 cells stably transfected with viral oncogenic forms of Src, Ha-Ras and Raf. PC-Src, PC-Ras and PC-Raf cells, like PC-PTC, have lost the dierentiated phenotype and TSH-dependency (Fusco et al., 1987) . None of these cells contained stress ®bers (Figure 1a ). In PC-Src cells, round aggregates of actin were identi®ed at the edge of the plasma membrane as described in other cell types (Abram and Courtneidge, 2000) . No speci®c actin rearrangement was observed in PC-Raf cells; membrane rues were found at the edges of cellular protrusions in PC-Ras. Finally, v-Ha-Ras expression in PC-PTC cells (Santoro et al., 1993) abrogated stress ®bers formation (Figure 1a) , suggesting that the RET/ PTC1-mediated eects exerted on cytoskeleton are reversible and can be obstructed by activation of the Ras signaling pathway. Few actin rues were detected in PC-PTC/Ras cells ( Figure 1a) .
We investigated actin reorganization in PC Cl 3 cells upon microinjection of an expression vector for a myc epitope-tagged RET/PTC1; as a negative control, we used the empty vector. Stress ®bers were detected as early as 4 h after RET/PTC1 injection, implying that this phenomenon is an early consequence of RET/PTC expression and not a late, secondary eect of thyroid cell transformation by RET/PTC1 (Figure 1b) . Furthermore, formation of stress ®bers was dependent on the kinase activity of RET/PTC1 because a kinasedead RET/PTC1 myc mutant (PTC1K-) failed to induce stress ®bers even days after injection ( Figure  1b) . Indirect immuno¯uorescence against the myc tag was performed to identify cells that had been injected with the RET/PTC1 constructs (not shown).
RET kinase activation causes autophosphorylation of many tyrosine residues. Among these, Y1062 plays a special role being involved in recruiting several docking proteins (Asai et al., 1996; Arighi et al., 1997; Lorenzo et al., 1997; Durick et al., 1998; Besset et al., 2000; Hayashi et al., 2000; Melillo et al., 2001a, b) and in the activation of many signaling pathways (De Vita et al., 2000; Segoun-Cariou and Billaud, 2000; Hayashi et al., 2000) . We used anti-pY1062 anti-RET blocking antibodies to interfere with RET/PTC signaling. Anti-pY1062 selectively recognize the Y1062-phosphorylated versions of RET and RET/PTC proteins and blocks RET/PTC1 signaling thereby obstructing RET/PTC1-mediated cell proliferation (Salvatore et al., 2000) . Injection of anti-pY1062 in PC-PTC cells abrogated stress ®bers, demonstrating that the organization of actin bundles in stress ®ber formations depends on continuous signaling by RET/PTC1. This inhibition was not observed when control puri®ed rabbit IgG was injected (Figure 1c ). Injected cells were identi®ed by immuno-¯u orescence with¯uorescein-conjugated anti-rabbit IgG (not shown). To formally prove the role of Y1062, we have expressed in PC Cl 3 cells a RET/PTC1 mutant carrying the mutation of tyrosine 451, the residue corresponding to Y1062 in full-length RET. Notably, phalloidin staining revealed no stress ®bers in PC-PTC(Y1062F) cells proving the essential role played by Y1062 in cytoskeleton organization ( Figure 1d familial cancer disease predisposing to neural crest derived neoplasms. RET/MEN 2A is activated by an extracellular domain point mutation that replaces cysteine 634 with a tyrosine (C634Y). This mutation causes ligand-independent dimerization of the receptor mediated by disul®de bonds (Santoro et al., 1995a) . Therefore, RET/MEN 2A is a trans-membrane protein, whereas RET/PTC chimeric proteins, as a consequence of truncation of the extracellular and transmembrane domains, are prevalently cytosolic (Durick et al., 1998) . We analysed the actin cytoskeleton in PC Cl 3 cells transfected with a RET/MEN 2A construct. Surprisingly, PC-MEN 2A cells did not form stress ®bers even 24 h after plating ( Figure 2a) ; rather, phalloidin staining of PC-MEN 2A revealed several convoluted membrane rues, which were absent from both parental and PTC-expressing cells. Therefore, RET/ PTC1-mediated stress ®ber formation does not solely depend on the kinase activation of RET; indeed it is a speci®c property of rearranged RET-derived oncogenes. Since stress ®bers formation was found to be dependent on Y1062, we investigated whether signaling pathways known to be dependent on such tyrosine were dierentially activated in RET/PTC1 and RET/ MEN 2A expressing cells. The immunoblot reported in Figure 2b shows that thyroid cells express comparable levels of the two RET oncoproteins. Therefore, we investigated Shc phosphorylation (by immunoblot with anti-phosphotyrosine antibodies), MAPK (Mitogen Activated Protein Kinase) activation (by immunoblot with antibodies speci®c for the phosphorylated and active p44 and p42 ERK) and JNK (c-Jun N-terminal Kinase) activation (by immunoblot with antibodies speci®c for the phosphorylated JNK). Surprisingly, the three pathways were signi®cantly more active in cells expressing RET/PTC1 than in cells expressing RET/ MEN 2A (Figure 2b ). Although these results do not allow to draw ®rm conclusions on which is the signaling pathway(s) responsible for the peculiar actin reorganization induced by RET/PTC1 in thyroid cells, they suggest that the increased signaling ability of RET/PTC1 to multiple signaling pathways may play a role in the establishment of this phenotype. Finally, we investigated actin reorganization in ®broblasts (NIH3T3) and mammary epithelial (MCF7) cells after microinjection of the RET/PTC1myc expression vector. Neither NIH3T3 nor MCF7 cells formed stress ®bers after injection of RET/PTC1, indicating that RET/PTC1 elicits a signaling pathway selective for thyroid cells (data not shown).
Cells derived from RET/PTC1-positive thyroid papillary carcinomas contain stress fibers RET/PTC1 rearrangements have been observed in approximately 40% of human thyroid papillary carcinomas whereas they are absent from follicular and anaplastic carcinomas of the thyroid (Jhiang, 2000) . To ascertain whether stress ®bers were a characteristic of tumoral cells harboring RET/PTC oncogenes, we investigated actin organization in two cell lines derived from human papillary thyroid carcinomas harboring RET/PTC1 rearrangements, TPC (Ishizaka et al., 1990) and FB2 (Basolo F, Santoro M and Fusco A, unpublished) , and in cells derived from anaplastic (ARO), follicular (WRO) and papillary (NIM and NPA) thyroid carcinomas negative for RET/PTC expression (Fagin et al., 1993) . TPC (Figure 3, upper) and FB2 (not shown) cells formed thick, long stress ®bers as early as 4 ± 6 h after plating, whereas ARO and WRO cells formed only very short, fragmented stress ®bers 10 ± 12 h after plating (not shown). Finally, NIM (Figure 3, upper) and NPA (not shown) cells were completely devoid of stress ®bers. To verify that stress ®bers in TPC cells depended on RET/ PTC1 expression, we injected the cells 2 h after plating with the anti-RET blocking antibodies. Cells were stained with rhodamine-conjugated phalloidin 2 h after microinjection (Figure 3 , lower) or later (not shown). Non-immune puri®ed rabbit IgG was used as control. Anti-RET antibodies prevented stress ®ber formation in TPC cells (Figure 3, lower) . Injected cells were identi®ed by indirect immuno¯uorescence with¯uor-escein-conjugated anti-rabbit IgG.
The Rho small GTPase is responsible for stress fiber formation in PC-PTC and TPC cells
In Swiss 3T3 ®broblasts, activated Rho GTPase induces stress ®bers and is necessary for stress ®ber formation upon stimulation by lysophosphatidic acid (LPA). In contrast, in the same cell line, activation of Rac produces membrane rues . To understand whether the two small GTPbinding proteins were involved in RET/PTC1-mediated cytoskeleton remodeling, PC-PTC and TPC cells were microinjected with dominant interfering Rac (RacN17) or Rho (RhoN19) plasmids (Rodriguez-Viciana et al., 1997) together with a plasmid encoding auto¯uorescent pEGFP as a tracer. Alternatively, we used the C3 toxin from Clostridium botulinum, a bacterial exoenzyme that selectively ADP-ribosylates and inhibits Rho together with puri®ed non-immune rabbit IgG to reveal injected cells. Actin ®laments were stained 2 h (Figure 4a ) or 4 h (not shown) after injection. Microinjection of C3 or RhoN19 prevented stress ®bers formation in PC-PTC and TPC cell lines. In contrast, RacN17 injection did not produce any signi®cant eect (Figure 4a ).
To verify whether Rho activation was sucient to induce stress ®bers in thyroid cells, we microinjected PC Cl 3 cells with a constitutively active Rho puri®ed protein (RhoV14) (Rodriguez-Viciana et al., 1997) or control IgG (Figure 4b ). RhoV14 promptly induced stress ®ber formation in PC Cl 3 cells. In contrast, the injection of puri®ed active Rac protein (RacV12) induced membrane rues (Figure 4b Therefore, we asked whether Rho might be involved in DNA synthesis and/or survival of RET/PTC1-expres- Figure 5) . Notably, C3 reduced BrdU incorporation in PC-PTC and TPC (about 10-fold) cells. C3 signi®cantly inhibited also parental NIH3T3 cells ( Figure 5 ). Exit from cell cycle was probably mainly due to the pro-apoptotic eect of Rho blocking in PC-PTC cells. Indeed, when C3 transferase was injected, more than 80% of PC-PTC and about 60% of TPC cells presented apoptotic nuclei at Hoechst staining (the average results of three independent experiments are shown in Figure 6a and representative microscopic ®elds in Figure 6b To ascertain whether these eects were speci®c for Rho, we used the dominant inhibitory RacN17 construct to disrupt Rac activation in the three cell types examined, and evaluated cell proliferation by measuring BrdU incorporation and apoptosis by These data indicate that RET/PTC1 expression in thyroid cells, but not in ®broblasts, shifts the control of proliferation from an Rac-dependent to an Racindependent pathway and engages an Rho-dependent pathway that is essential for cell survival.
Discussion
The restriction of RET/PTC expression to thyroid tumors of the papillary subtype suggests that RET/ PTC kinase is linked to speci®c signaling pathways in thyroid epithelial cells. Here we describe a RET/PTCdriven pathway that is restricted to thyroid cells among the cell types analysed. Analysis of the organization of the actin cytoskeleton showed that RET/PTC triggers the formation of stress ®bers. Stress ®bers were dependent on Rho GTPase in RET/PTC-transfected thyroid cells. Although our results apply to cultured cell lines, the presence of RET/PTC-dependent stress ®bers also in TPC and FB2 carcinoma cells, spontaneously harboring the RET/PTC1 rearrangement, supports the possibility that this phenotype is correlated to RET/PTC also in in vivo conditions. The organization of actin ®laments into a stress ®ber formation is not the general response of thyroid cells to neoplastic transformation because other categories of oncogenes (Src, Ras and Raf) did not induce this phenotype. For example, Ras expression induced the formation of membrane rues, an actin arrangement that is secondary to activation of Rac GTPase . Whereas RET/PTC oncogene activation is restricted to papillary carcinomas of the thyroid, Ras activation is very frequent in tumors of the follicular subtype (Santoro et al., 1995b) . Papillary and follicular carcinomas are characterized by several distinctive morphological and biological features (Schlumberger, 1998) . Consequently, Ras and RET/PTC oncogenes have been predicted to induce dierent phenotypes in Initial studies performed in Swiss 3T3 cells showed that Cdc42, Rac and Rho are organized in hierarchical cascades wherein activated Cdc42 leads to activation of Rac, which, in turn, activates Rho (Nobes and Hall, 1995) .
However, this epistatic arrangement (Cdc424Rac4Rho) is challenged by observations in other cellular systems (Moorman et al., 1999) . For instance, Rac and Rho can be activated by distinct sets of agonists. G-protein-coupled receptors (GPCR), such as the LPA receptor, activate Rho (Kjoller and Hall, 1999) . In contrast, Rac is activated in response to a range of tyrosine kinase receptors (RTK), i.e. insulin, PDGF, HGF, CSF and EGF receptors. RTK-mediated activation of Rac is mediated by Ras and phosphoinositide 3 kinase (Scita et al., 1999) . Less is known about Rho activation mediated by tyrosine kinases; EGFR was found to be a weak Rho activator (Kjoller and Hall, 1999) . It has been also proposed that Cdc42/ Rac and Rho may act antagonistically so that inhibition of a given Rho family of GTPases leads to a phenotype consistent with activation of the other Rho family GTPase (Kjoller and Hall, 1999; Moorman et al., 1999) . For instance, activation of Rac in the N1E-115 neuroblastoma cell line promotes neurite extensions subsequent to lamellipodia formation, whereas activation of Rho induces neurite retraction (Kozma et al., 1997) . Although the molecular basis of this mutual antagonism is not clear, it can be a way to regulate partitioning of the actin pool into the dierently organized cytoskeletal structures (Kjoller and Hall, 1999) . In the thyroid cell system described here, Rho and Rac appear to work antagonistically and are mutually exclusive.
Here we show that Rho activity is also necessary for the survival of RET/PTC-expressing PC Cl 3 cells. This ®nding coincides with an earlier report that cell survival can be regulated by a Rho-mediated signaling pathway (Moorman et al., 1999) . Furthermore, Rho is a crucial component of survival signaling pathways in thymocytes (Costello et al., 2000) . These results suggest that pharmacological inhibition of Rho may be a realistic therapeutic strategy for human RET/PTCexpressing papillary thyroid carcinomas.
Activation of the`Rho pathway' in thyroid cells depends on the kinase activity of the RET/PTC protein. RET/PTC (chimeric protein with a dimerization motif) and RET/MEN 2A (mutant in an extracellular cysteine) induced dierent actin arrangements in thyroid cells, although both oncoproteins are endowed with constitutive kinase activity: PC-PTC cells formed Rho-dependent stress ®bers, and PC-MEN 2A cells formed membrane rues. To our knowledge, this is the ®rst demonstration of dierential signaling of the two oncogenic forms of RET and, more in general, of RTKs activated by dierent types of mutation. Conceivably, the structural diversity or the dierent subcellular localization of the two oncoproteins may contribute to this signaling diversity. Indeed, it is possible that the RET fusion partner aects RET/ PTC coupling to components of the Rho GTPases activation pathway, thereby causing the dierence between RET/PTC and RET/MEN 2A in modulating Rho GTPases. Another possibility is that the dierent localization of the two proteins, RET/PTC and RET/ MEN 2A, may enable coupling with dierent activators of the small GTPases. Intriguingly, tyrosine 1062 was found to be necessary for the stress ®bers formation induced by RET/PTC1. Although also RET/MEN 2A carries this phosphoresidue, pathways initiated at the level of pY1062 are signi®cantly more active in PTC than in MEN 2A-expressing cells suggesting that quantitative signaling dierences can cause the divergences in cytoskeleton organization promoted by the two RET oncoproteins.
It has been reported that cyclic AMP induces rapid morphological changes of dog thyroid cells associated with complete disruption of actin containing stress ®bers (Roger et al., 1988) . We noticed a virtually complete disruption of the stress ®bers in PC-PTC and TPC cells upon treatment with cAMP (10 mM) for 24 h (data not shown). Cyclic AMP treatment caused also an increase of membrane rues. These results suggest that cAMP activates a parallel pathway involving Rac stimulation or, alternatively, Rho inhibition, leading to the obstruction of RET/PTC-induced actin remodeling.
By regulating actin reorganization, cell motility, adhesion and survival, Rho family proteins act as key molecular switches to drive morphogenesis (Kjoller and Hall, 1999) . Papillary carcinomas of the thyroid are Figure 7 Rac inhibition does not interfere with proliferation of RET/PTC1-expressing thyroid cells. RacN17 plasmid together with pEGFP or the empty vector together with pEGFP were injected in parental PC Cl 3 and NIH3T3 cells, PC-PTC, TPC and NIH-PTC cells. BrdU was added, as described in Figure 4 , and cells were ®xed and processed for immuno¯uorescence: antiBrdU, monitored by a Texas red-conjugated anti-mouse antibody, was used to detect the fraction of cells in S phase and¯uorescein-conjugated anti-rabbit IgG was used to detect microinjected cells. The average results of three independent experiments in which at least 60 injected cells were counted are reported with standard deviations as percentage of injected cells that were BrdU-positive characterized by speci®c morphological features (papillae), nuclear features (nuclear grooves and groundglass nuclei), and the tendency to invade lymphatics rather than blood vessels (Schlumberger, 1998) . It is tempting to speculate that the RET/PTC4Rho pathway described herein plays a role in determining such a peculiar tumor phenotype.
Materials and methods
Expression plasmids and antibodies
Expression plasmids for RhoN19 and RacN17 were kindly donated by J Downward (Rodriguez-Viciana et al., 1997) . RET/PTC1 cDNA was cloned in the pCDNA3(Myc-His) vector (Invitrogen, Groningen, The Netherlands) fused inframe at the C-terminus with a myc epitope and a His tag. The RET plasmid encoding the MEN 2A-associated mutation, C634Y is described elsewhere (Santoro et al., 1995a) . The kinase-dead myc-tagged RET/PTC1 mutant (carrying the substitution of the catalytic lysine, K758, with a methionine residue) and the myc-tagged RET/PTC1 mutant carrying the substitution of tyrosine 451 (the residue corresponding to tyrosine 1062 in full-length RET) to phenylalanine were generated using the QuickChange mutagenesis kit (Stratagene, La Jolla, CA, USA). The mutations were con®rmed by DNA sequencing.
Secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phosphoRET antibodies were raised in rabbits against a tyrosine-phosphorylated 20mer peptide that maps in the RET C-terminal tail and contains phosphorylated tyrosine 1062 (anti-pY1062). The antibodies were anity puri®ed through sequential chromatographic steps as reported elsewhere (Salvatore et al., 2000) . Phosphorylation of Shc, MAPK and JNK was assessed as reported elsewhere (Melillo et al., 2001b) .
Cell culture
The RET/PTC1-transformed NIH3T3 cells (NIH-PTC) are described elsewhere (Grieco et al., 1990) . Parental NIH3T3 and NIH-PTC ®broblasts were grown in Dulbecco Modi®ed Eagle's Medium (DMEM) supplemented with 10% calf serum and 100 units/ml of penicillin and streptomycin (Gibco BRL, Paisley, PA, USA). TPC (Ishizaka et al., 1990) and FB2 (Basolo F, Santoro M and Fusco A, unpublished) cells were derived from papillary carcinomas harboring the RET/ PTC1 rearrangement. ARO and WRO cells were derived from anaplastic and follicular thyroid carcinomas, respectively (Fagin et al., 1993) . Human thyroid cell lines were grown in DMEM supplemented with 10% calf serum and antibiotics. PC Cl 3 is a thyroid epithelial cell line derived from 18-month-old Fischer rats. PC Cl 3 cells were cultured in Coon's modi®ed F12 medium supplemented with 5% calf serum and a mixture of thyrotropin, hydrocortisone, insulin, transferrin, somatostatin and glycyl-histidyl-lysine (Sigma Chemical Co., St. Louis, MO, USA) according to Fusco et al. (1987) . The PC-PTC1 cells were obtained by transfecting the RET/PTC1 oncogene in PC Cl 3 cells (Santoro et al., 1993) . PC-PTC1/Ras were obtained by infecting PC-PTC with a retrovirus carrying the v-Ha-Ras oncogene (Santoro et al., 1993) . PC-PTC1(Y1062F) and PC-MEN 2A cells were obtained by transfection and marker selection of mass population of several hundred clones. Expression levels of RET protein products in PC-PTC and PC-PTC(Y1062F) cells were comparable (not shown). PC-Src, PC-Ras and PC-Raf cells were derived from PC Cl 3 cells upon expression of vSrc, v-Ki-Ras and v-Raf oncogenes as previously described (Fusco et al., 1987) .
Microinjection of cells
Cells were plated on glass coverslips and injected with a semiautomatic apparatus (Eppendorf, Netheler, Germany) 2 ± 4 h after plating. Each experiment was repeated three times and for each single experiment at least 60 injected cells were counted. The phenotype was considered representative when present in more than 90% of the injected cells. The RhoV14 and RacV12 puri®ed proteins, kindly donated by Dr J Downward (Rodriguez-Viciana et al., 1997) , were injected at a concentration of 2 mg/ml together with puri®ed rabbit IgG (2 mg/ml; Sigma Chemical Co.) to visualize injected cells. IgG (2 mg/ml) alone was injected for a negative control. Exotoxin C3 (Calbiochem, San Diego, CA, USA) was injected at a concentration of 150 mg/ml together with the IgG tracer (2 mg/ml; Sigma Chemical Co.). Anity-puri®ed anti-RET (anti-pY1062) antibodies were injected at a concentration of 2 mg/ml; as a control, non-immune puri®ed rabbit IgG was used at the same concentration. The plasmids encoding Rho N19 and Rac N17 were injected at a concentration of 30 ng/ ml together with the plasmid encoding Green Fluorescent Protein (pEGFP from Clontech) at a concentration of 30 ng/ ml to identify injected cells. As a control, we used the empty vector and pEGFP. The plasmids encoding myc-tagged RET/ PTC1 variants were injected at a concentration of 100 ng/ml together with the plasmid encoding for Green Fluorescent Protein (pEGFP from Clontech) at a concentration of 30 ng/ ml to identify injected cells. As a control, we used the empty vector and pEGFP. When plasmids were injected, the experiment was stopped 4 h after the injection; when proteins or antibodies were injected the experiments were stopped after 2 h. For S phase entry measurements, proteins, antibodies and plasmid DNA were used at the concentrations indicated above. Bromodeoxyuridine (BrdU; Sigma Chemical Co.) was added to the cell culture media at a ®nal concentration of 100 mg/ml 18 h after the injection and 1 h before permeabilizing and ®xing the sample.
Cell staining
Cells were seeded on glass coverslips, permeabilized with Triton X-100 (0.2%) and ®xed with paraformaldehyde (4%) prior to staining. Actin rearrangements were revealed by treating coverslips with rhodamine-conjugated phalloidin (Sigma Chemical Co.) for 1 h. Co-injected IgG was revealed with ā uorescein-conjugated anti rabbit antibody (0.2 mg/ml for 1 h at room temperature) before mounting with Moviol (Sigma Chemical Co.). When plasmid DNA and pEGFP were injected together, only rhodamine-conjugated phalloidin staining was used. BrdU incorporation was evaluated as described elsewhere (Barone and Courtneidge, 1995) . Brie¯y, coverslips were incubated with anti-BrdU mouse monoclonal antibody and then with a Texas red-conjugated anti-mouse antibody (Boehringer Mannheim, Germany) to detect the fraction of cells in S phase. Fluorescein-conjugated anti-rabbit IgG was used to detect microinjected cells. All coverslips were ®nally counterstained in PBS containing Hoechst 33258 (®nal concentration, 1 mg/ml; Sigma Chemical Co.), rinsed in water and mounted in Moviol on glass slides. The¯uorescent signal was visualized with an epi¯uorescent microscope (Axiovert 2, Zeiss) (equipped with 406 or 1006 objectives for Figure 1d and all the other Figures, respectively) interfaced with the image analyser software KS300 (Zeiss).
